Skip to content

Advertisement

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Risk and predictors of psoriasis in patients with breast cancer: a Swedish population-based cohort study

  • Haomin Yang1Email author,
  • Judith S. Brand1,
  • Jingmei Li1,
  • Jonas F. Ludvigsson1, 2,
  • Emilio Ugalde-Morales1,
  • Flaminia Chiesa1,
  • Per Hall1 and
  • Kamila Czene1
BMC Medicine201715:154

https://doi.org/10.1186/s12916-017-0915-4

Received: 23 March 2017

Accepted: 18 July 2017

Published: 11 August 2017

Abstract

Background

The risk of psoriasis in patients with breast cancer is largely unknown, as available evidence is limited to case findings. We systematically examined the incidence and risk factors of psoriasis in patients with breast cancer.

Methods

A Swedish nationwide cohort of 56,235 breast cancer patients (2001–2012) was compared to 280,854 matched reference individuals from the general population to estimate the incidence and hazard ratio (HR) of new-onset psoriasis. We also calculated HRs for psoriasis according to treatment, genetic, and lifestyle factors in a regional cohort of 8987 patients.

Results

In the nationwide cohort, 599 patients with breast cancer were diagnosed with psoriasis during a median follow-up of 5.1 years compared to 2795 cases in the matched reference individuals. This corresponded to an incidence rate of 1.9/1000 person-years in breast cancer patients vs. 1.7/1000 person-years in matched reference individuals. Breast cancer patients were at an increased risk of psoriasis (HR = 1.17; 95% confidence interval (CI) = 1.07–1.28), especially its most common subtype (psoriasis vulgaris; HR = 1.33; 95% CI = 1.17–1.52). The risk of psoriasis vulgaris was highest shortly after diagnosis but remained increased up to 12 years. Treatment-specific analyses indicated a higher risk of psoriasis in patients treated with radiotherapy (HR = 2.44; 95% CI = 1.44–4.12) and mastectomy (HR = 1.54, 95% CI = 1.03–2.31). Apart from treatment-specific effects, we identified genetic predisposition, obesity, and smoking as independent risk factors for psoriasis in breast cancer patients.

Conclusions

The incidence of psoriasis is slightly elevated among patients with breast cancer, with treatment, lifestyle, and genetic factors defining the individual risk profile.

Background

Psoriasis is a complex autoimmune skin disorder characterized by patches of abnormal skin. The prevalence of the condition has been estimated to be between 2% to 3% in the general population of Western countries [1, 2]. Common symptoms include red, inflamed skin and scaly plaques. More severe complications, such as inflammatory arthritis, can result in joint deformations and disability. Patients suffering from psoriasis typically report a poor health-related quality of life and endure significant social stigma [35].

Clinical observations suggest a potential increased risk of psoriasis in patients with breast cancer, which has mainly been attributed to skin trauma due to surgery [6] or radiotherapy-induced skin reactions [7]. Estimates of the incidence and relative risk of psoriasis as compared to the general population, however, are unknown, as the available evidence is limited to case reports with a predominant focus on patients who were previously diagnosed with psoriasis [811]. Moreover, no study to date has systematically examined the impact of different treatment-related factors including surgery and radiotherapy on psoriasis incidence, despite the fact that skin trauma has been shown to be a triggering factor for more than half of the new-onset psoriasis cases [12]. Considering the rising incidence of breast cancer and the large proportion of patients undergoing radiotherapy and surgery, it is of importance to better understand the risk of psoriasis in women treated with such modalities.

Psoriasis is an autoimmune disease with genetic variants and lifestyle factors (including alcohol consumption, smoking, and obesity) influencing disease susceptibility [1316]. Since cancer cells and immunosuppressive cancer treatments including chemotherapy can influence the immune system of patients with breast cancer, the contribution of genetic and lifestyle factors to psoriasis risk may be different in this patient population [17]. Whether risk factors identified in the general population predispose to psoriasis in these patients, however, has not been assessed previously.

We aimed to assess the relative risk and incidence rates of psoriasis in patients with breast cancer as compared to the general population, overall and by time since diagnosis. We specifically evaluated risks by radiotherapy and surgery as sources of skin trauma-triggering events. We also studied the impact of previously identified psoriasis risk factors (i.e., genetic predisposition and lifestyle factors) to comprehensively understand the factors influencing disease susceptibility in this patient population.

Methods

Study populations

We analyzed two population-based cohorts: a Swedish nationwide cohort of breast cancer patients and a regional breast cancer cohort (Table 1, Additional file 1: Figure S1).
Table 1

Descriptive characteristics of the nationwide and regional breast cancer cohorts

 

Nationwide cohort n = 56,235

Regional cohort n =8987

Cohort period

2001–2012

2001–2013

Age at diagnosis (years)

 Mean (SD)

60.1 (11.0)

58.6 (11.2)

 Minimum–maximum

20–80

23–80

Duration of follow-up (years)

 Median (IQR)

5.1 (5.4)

7.7 (4.3)

Total no. of person-years at risk

307,684

68,243

Cases of psoriasis

599

150

Age at psoriasis diagnosis (SD)

62.5 (10.0)

63.6 (10.2)

SD standard deviation, IQR interquartile range

The nationwide cohort includes women diagnosed with primary invasive breast cancer at age 20–80 years between 2001 and 2011. In this cohort, follow-up is complete until 31 December 2012. The regional cohort includes women diagnosed with primary invasive breast cancer at age 20–80 years between 2001 and 2008; all patients in this cohort have complete follow-up until 31 December 2013

The nationwide cohort of breast cancer patients comprised women who were part of the 1990 national census of Sweden and were diagnosed with primary invasive breast cancer between 2001 and 2011, at age 20–80 years (n = 56,976). Information on breast cancer diagnoses was obtained through the Swedish Cancer Register, which was founded in 1958 and is managed by the National Board of Health and Welfare. Since the focus of our study is on the risk of new-onset psoriasis, patients who had been diagnosed with psoriasis before the date of the breast cancer diagnosis were excluded, leaving 56,235 patients in the cohort (Table 1). To compare the risk of psoriasis, we randomly sampled up to 5 women from the general female population matched on age, county of residence, and social economic status (obtained from the 1990 national census of Sweden, categorized as blue collar workers, white collar workers, self-employed workers, farmers, and others). Each reference individual was alive and free of cancer and psoriasis on the date of the matched patient’s diagnosis (the index date). In total, 321 women could not be matched to an index case, resulting in 280,854 matched reference individuals. Follow-up of the cohorts started from the index date (i.e., diagnosis date for breast cancer patients) and ended on 31 December 2012, date of death, date of emigration, date of a secondary cancer diagnosis, or date of psoriasis diagnosis, whichever came first. Information on death and emigration was obtained through cross-linking the cohorts to the Swedish Causes of Death Register and the Swedish Migration Register, using the unique personal identity number.

LIBRO-1 is a regional breast cancer cohort including women diagnosed with primary invasive breast cancer (at age 20–80 years) between 2001 and 2008 in the Stockholm-Gotland area (n = 8987). Detailed information on tumor characteristics and treatment at baseline was available in LIBRO-1 through linkage to the Swedish breast cancer quality registers (Information Networks for Cancer Treatment and Regional Cancer Center Stockholm-Gotland), including tumor size, estrogen receptor status, metastasis status, as well as information on intended treatment in terms of surgery, radiotherapy, chemotherapy, and endocrine therapy. The LIBRO-1 cohort was linked to the Swedish Causes of Death Register and the Swedish Migration Register to obtain information on date of death and emigration. Person-time was defined in the same way as for the nationwide cohort, except for an extension of the follow-up until 31 December 2013.

Psoriasis diagnoses

All psoriasis cases were identified through the Swedish Patient Register [18], which was established in 1964 and achieved nationwide coverage for inpatient hospitalizations in Sweden since 1987. From 2001, hospital-based outpatient physician visits have also been reported by Swedish counties. Diagnoses were coded according to the 7th–10th Swedish Revision of the International Classification of Diseases (ICD) codes (ICD-7 (1964–1968): 706; ICD-8 and ICD-9 (1969–1996): 696; ICD-10 (1997–present): L40). The validity of a psoriasis diagnosis in the inpatient and outpatient registers is 81% [19]. The first psoriasis subtype recorded was defined by the use of the ICD-10 code into: psoriasis vulgaris (L40.0), palmoplantar pustulosis (L40.3), and arthropathic psoriasis (L40.5). To ensure specificity, only primary discharge diagnoses were considered for the present analysis.

Genetic and lifestyle risk factors

A subset of 4365 breast cancer patients within LIBRO-1 who were alive in 2009 consented to participate in a questionnaire-based study and gave a blood sample for genetic analyses. Patients’ lifestyle information on cigarette smoking, body mass index (BMI), alcohol consumption, and physical activity prior to diagnosis was retrieved from the self-reported questionnaire. Genotyping was carried out using a custom Illumina iSelect array (iCOGS) comprising 211,155 single nucleotide polymorphisms (SNPs) [20]. Details of the iCOGS array design, sample handling, and quality control processes have been described elsewhere [20]. To assess genetic predisposition to psoriasis, we selected 35 genome-wide significant SNPs reported by a recent meta-analysis of psoriasis genome-wide association studies (GWASs) [21] for constructing a polygenic risk score (PRS) using a scoring routine in the PLINK software v1.9 [22]. All SNPs were not directly genotyped on iCOGS, but imputed instead using the 1000 Genomes Project March 2012 release as a reference [23]. All SNPs passed quality control (minor allele frequency (MAF) ≥ 0.01 and R2/IMPUTE info-score ≥ 0.5), and for each individual breast cancer patient, a weighted PRS was calculated using the following formula:
$$ \mathrm{P}\mathrm{R}\mathrm{S}={\beta}_1{x}_1+{\beta}_2{x}_2+....{\beta}_k{x}_k+{\beta}_n{x}_n $$
where β is the per-allele log odds ratio (OR) for psoriasis associated with the risk allele for SNP k , x k is the number of alleles for the same SNP (0, 1, 2), and n is the total number of disease SNPs included in the profile. The SNPs and corresponding ORs (weights) used for the derivation of the PRS are summarized in Additional file 1: Table S1. For analysis, patients were categorized by tertiles of the PRS.

Statistical analysis

To assess the risk of psoriasis in patients with breast cancer, we used stratified Cox regression models (i.e., Cox regression models conditioned on the matching variables age, county of residence, and social economic status) and calculated hazard ratios (HRs) for psoriasis in patients with breast cancer, overall, and by dividing the follow-up time into periods of 0 to < 0.5 year, 0.5 to < 1 year, 1–5 years, and >5 years, and by age at diagnosis (20–44 years, 45–54 years, 55–64 years, and 65–80 years). The underlying time scale for all the analyses was time since diagnosis. The stratified Cox model has been a recommended analysis approach for matched cohort data, and it deals with the presence of potential confounders (measured and unmeasured) as well as any imbalances in the matching scheme caused by censoring [2426]. Potential effect modification of age was tested by adding an interaction term of breast cancer (yes vs. no) with age (20–44 years, 45–54 years, 55–64 years, and 65–80 years) to the Cox model. We used Kaplan-Meier analyses to assess the cumulative incidence of psoriasis in breast cancer patients and matched reference individuals. This analysis approach does not account for the competing risk of death. Therefore, to address this potential bias, we also analyzed the data using competing risk models, treating mortality as a competing event.

To identify the risk factors for psoriasis in patients with breast cancer, we analyzed associations with cancer treatment in the regional cohort of breast cancer patients. The basic model (Model 1) was adjusted for age at breast cancer diagnosis and calendar period. In the multivariable model (Model 2), all treatment variables were entered for mutual adjustment as fixed covariates. To investigate potential confounding by disease severity, a sensitivity analysis was conducted in which tumor characteristics were added to Model 2. We further studied the effect of genetic predisposition and lifestyle factors in the subcohort with questionnaire and genotyping data. These analyses were conducted in the same manner as the analysis of cancer treatments, with a basic model (Model 1) adjusting for age at breast cancer diagnosis and calendar period, and a multivariable model (Model 2) including all risk factors, including identified treatment-related risk factors. Ordinary Cox regression was used for all risk factor analyses, and the proportional hazards assumption was tested using Schoenfeld residuals.

Statistical analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA) and Stata software (version 14.0; Stata Corporation, College Station, TX, USA). The study was approved by the Regional Ethical Review Board in Stockholm.

Results

Risk of psoriasis in patients with breast cancer as compared to matched reference individuals

In total, 599 cases of psoriasis were observed during a median follow-up of 5.1 years in the nationwide breast cancer cohort compared to 2795 cases in the matched reference individuals. This corresponded to an incidence rate of 1.9/1000 person-years in breast cancer patients vs. 1.7/1000 person-years in the matched reference individuals, indicating a 0.2/1000 person-years of absolute risk increase (95% confidence interval (CI) = 0.1/1000–0.4/1000). The most common psoriasis subtype was psoriasis vulgaris (298 out of 599), followed by palmoplantar pustulosis and arthropathic psoriasis. The 5-year cumulative incidence of psoriasis in breast cancer patients and in the matched reference individuals was 1.0% and 0.8%, respectively (Fig. 1). These estimates were very similar to those observed in competing risk analyses, indicating that bias due to the competing risk of death is negligible.
Fig. 1

Cumulative incidence of psoriasis in the nationwide cohort of breast cancer patients and matched individuals. Kaplan-Meier estimates of the cumulative risk of psoriasis by time since diagnosis, in breast cancer patients and matched individuals from the general population

Patients with breast cancer experienced a 17% increased risk of being diagnosed with psoriasis during follow-up (HR = 1.17; 95% CI = 1.07–1.28) (Table 2). The increased risk of psoriasis was mainly attributed to psoriasis vulgaris (HR = 1.33, 95% CI = 1.17–1.52), with no overall risk increase being observed for the other psoriasis subtypes. Analyses by time since diagnosis showed that the risk of psoriasis was highest in the second half of the first year after diagnosis (HR = 1.68, 95% CI = 1.30–2.19). The risk of psoriasis vulgaris was long-term increased, with the HR remaining significant between 5 and 12 years after diagnosis (HR = 1.33, 95% CI = 1.06–1.68). Risk of psoriasis did not vary among different age groups, and the interaction between a breast cancer diagnosis and age was not significant (P for interaction = 0.84).
Table 2

Hazard ratios for psoriasis in the nationwide breast cancer cohort

 

No. of PYs

Any psoriasis

Psoriasis vulgaris

Palmoplantar pustulosis

Arthropathic psoriasis

Total/case no.

HR (95% CI)

Case no.

HR (95% CI)

Case no.

HR (95% CI)

Case no.

HR (95% CI)

Overall

 Matched reference cohort

1,666,038

280,854/2795

1.00 (Ref.)

1234

1.00 (Ref.)

488

1.00 (Ref.)

433

1.00 (Ref.)

 Breast cancer cohort

307,684.8

56,235/599

1.17 (1.07–1.28)

298

1.33 (1.17–1.52)

95

1.04 (0.84–1.30)

75

0.94 (0.73–1.20)

Time since diagnosis

0 to < 0.5 year

  Matched reference cohort

139,886.5

280,854/238

1.00 (Ref.)

86

1.00 (Ref.)

48

1.00 (Ref.)

51

1.00 (Ref.)

  Breast cancer cohort

27,780.35

56,235/50

1.08 (0.80–1.47)

23

1.35 (0.85–2.14)

13

1.40 (0.76–2.59)

4

0.41 (0.15–1.13)

0.5 to < 1 year

  Matched reference cohort

138,587.1

278,473/228

1.00 (Ref.)

113

1.00 (Ref.)

27

1.00 (Ref.)

32

1.00 (Ref.)

  Breast cancer cohort

27,301.1

55,033/75

1.68 (1.30–2.19)

37

1.66 (1.15–2.41)

15

2.88 (1.52–5.43)

5

0.80 (0.31–2.07)

1–5 years

  Matched reference cohort

861,202.7

275,870/1451

1.00 (Ref.)

629

1.00 (Ref.)

281

1.00 (Ref.)

219

1.00 (Ref.)

  Breast cancer cohort

162,011.6

54,156/296

1.09 (0.96–1.24)

146

1.27 (1.06–1.52)

43

0.81 (0.58–1.12)

44

1.07 (0.77–1.48)

   > 5 years

  Matched reference cohort

526,362

159,147/878

1.00 (Ref.)

406

1.00 (Ref.)

132

1.00 (Ref.)

131

1.00 (Ref.)

  Breast cancer cohort

90,591.81

28,430/178

1.17 (0.99–1.38)

92

1.33 (1.06–1.68)

24

1.02 (0.66–1.60)

22

0.98 (0.62–1.56)

Age at breast cancer diagnosis

20–44 years

  Matched reference cohort

158,527.2

25,361/185

1.00 (Ref.)

75

1.00 (Ref.)

30

1.00 (Ref.)

46

1.00 (Ref.)

  Breast cancer cohort

28,908.36

5099/43

1.35 (0.97–1.90)

24

1.88 (1.17–3.00)

6

1.08 (0.45–2.62)

6

0.82 (0.35–1.94)

45–54 years

  Matched reference cohort

389,187.5

61,404/707

1.00 (Ref.)

285

1.00 (Ref.)

155

1.00 (Ref.)

122

1.00 (Ref.)

  Breast cancer cohort

72,753.48

12,289/151

1.16 (0.97–1.38)

72

1.39 (1.07–1.81)

28

0.95 (0.63–1.43)

22

0.97 (0.61–1.53)

55–64 years

  Matched reference cohort

549,425.4

89,347/1067

1.00 (Ref.)

447

1.00 (Ref.)

213

1.00 (Ref.)

172

1.00 (Ref.)

  Breast cancer cohort

102,753.2

17,850/229

1.14 (0.99–1.32)

109

1.27 (1.03–1.58)

42

1.04 (0.74–1.45)

23

0.74 (0.47–1.15)

65–80 years

  Matched reference cohort

568,898.3

104,742/836

1.00 (Ref.)

427

1.00 (Ref.)

90

1.00 (Ref.)

93

1.00 (Ref.)

  Breast cancer cohort

103,269.8

20,997/176

1.16 (0.99–1.38)

93

1.27 (1.01–1.59)

19

1.21 (0.73–2.01)

24

1.30 (0.82–2.07)

CI confidence interval, no. number, PYs person-years, HR hazard ratio

Hazard ratio of psoriasis in the nationwide breast cancer cohort compared to age, residence place, and social economic status matched Swedish female population (age 20–80). Significant associations are denoted in boldface. P values for the test of interaction term of breast cancer diagnosis and age groups are 0.84, 0.49, 0.91, and 0.37, respectively, for psoriasis overall, psoriasis vulgaris, palmoplantar pustulosis, and arthropathic psoriasis

Risk of psoriasis by treatment, genetic predisposition, and lifestyle factors in patients with breast cancer

Analyses by treatment characteristics showed no effect of chemotherapy and endocrine therapy on psoriasis risk (Table 3). Radiotherapy, in contrast, was associated with a twofold increased risk after adjusting for surgery, chemotherapy, and endocrine therapy (HR = 2.44; 95% CI = 1.44–4.12). An increased risk of psoriasis was also observed in breast cancer patients who underwent mastectomy, compared to those who had a lumpectomy (HR = 1.54, 95% CI = 1.03–2.31) in the multivariable adjusted model (Model 2). A sensitivity analysis with additional adjustment for tumor characteristics yielded similar results (Additional file 1: Table S2).
Table 3

Hazard ratios for psoriasis in the regional breast cancer cohort according to treatment characteristics

 

Total no.

No. of cases

HR (95% CI)

 

Model 1

Model 2

Endocrine therapy

 No

1533

27

1.00 (Ref.)

1.00 (Ref.)

 Yes

7100

121

0.90 (0.59–1.36)

0.80 (0.52–1.24)

Chemotherapy

 No

5544

102

1.00 (Ref.)

1.00 (Ref.)

 Yes

3070

46

0.82 (0.57–1.19)

0.70 (0.47–1.04)

Radiotherapy

 No

2061

23

1.00 (Ref.)

1.00 (Ref.)

 Yes

6574

125

1.78 (1.14–2.78)

2.44 (1.44–4.12)

Surgery

 Lumpectomy

5203

94

1.00 (Ref.)

1.00 (Ref.)

 Mastectomy

3459

55

0.96 (0.69–1.34)

1.54 (1.03–2.31)

CI confidence interval, Total no. number of breast cancer patients, No. of cases number of psoriasis cases, HR hazard ratio

Model 1: adjusted for age and calendar period of breast cancer diagnosis. Model 2: Model 1 plus all the treatment factors. Significant associations are denoted in boldface. Missingness on all variables is <5%. No evidence of non-proportional hazards was found

Table 4 shows the association of genetic and lifestyle factors with psoriasis risk in patients with breast cancer. A significantly increased risk of psoriasis was found among patients in the highest tertile of the psoriasis PRS compared to those having lower genetic scores (HR = 2.94; 95% CI = 1.57–5.49, P for trend < 0.001). In the multivariable model (Model 2), regular cigarette smoking for more than 1 year prior to diagnosis (HR = 1.59; 95% CI = 1.00–2.52) and a BMI larger than 30 kg/m2 at diagnosis (HR = 2.10; 95% CI = 1.20–3.68) significantly increased the risk of psoriasis in breast cancer patients. In the multivariable model, a high level of physical activity (more than 2 h per week) prior to diagnosis was shown to protect breast cancer patients from psoriasis; however, this effect was not significant (HR = 0.59; 95% CI = 0.33–1.03).
Table 4

Hazard ratios for psoriasis in the regional breast cancer cohort according to genetic and lifestyle factors

 

Total no.

No. of cases

HR (95% CI)

Model 1

Model 2

PRS score

 Tertile 1

1440

13

1.00 (Ref.)

1.00 (Ref.)

 Tertile 2

1442

36

2.74 (1.45–5.17)

2.83 (1.50–5.34)

 Tertile 3

1483

40

2.94 (1.57–5.49)*

2.98 (1.59–5.58)*

BMI

  < 25 kg/m2

2331

40

1.00 (Ref.)

1.00 (Ref.)

 25–30 kg/m2

1434

28

1.18 (0.73–1.92)

1.15 (0.71–1.87)

  > 30 kg/m2

536

19

2.29 (1.32–3.98)

2.10 (1.20–3.68)

Physical activity per week

 0 h

762

21

1.00 (Ref.)

1.00 (Ref.)

 0–2 h

1645

36

0.77 (0.45–1.33)

0.77 (0.44–1.32)

  > 2 h

1910

30

0.56 (0.32–0.98)

0.59 (0.33–1.03)

Regular smoker (cigarette smoking >1 year)

 No

1773

26

1.00 (Ref.)

1.00 (Ref.)

 Yes

2546

62

1.65 (1.04–2.61)

1.59 (1.00–2.52)

Alcohol consumption

 No

104

2

1.00 (Ref.)

1.00 (Ref.)

 Yes

2861

58

1.03 (0.25–4.22)

1.12 (0.27–4.70)

Total no. number of breast cancer patients, No. of cases number of psoriasis cases, HR hazard ratio, CI confidence interval, BMI body mass index, PRS polygenic risk score

Analyses were based on a subset of the regional cohort with information on genetic and lifestyle factors. Significant associations are denoted in boldface. Genetic predisposition for psoriasis was defined by a PRS including 35 genetic variants for psoriasis susceptibility. Patients were grouped into tertiles by their genetic risk. Model 1: adjusted for age and calendar period of breast cancer diagnosis. Model 2: all of the risk factors were put into the model, including radiotherapy and mastectomy. Missingness on all variables is <5%, except for alcohol consumption (32.1%, N = 1400). No evidence of non-proportional hazards was found

*P for trend < 0.001, tested by log-linear trend test

Discussion

Key results

The incidence of psoriasis was 17% higher in breast cancer patients compared to the matched reference individuals in this study. The relative risk of psoriasis was seen within the first year after diagnosis and was mainly attributed to an increased risk of psoriasis vulgaris (33% higher). Treatment-specific analyses indicated an increased risk of psoriasis in patients treated with radiotherapy and mastectomy. Apart from treatment-specific effects, we identified genetic predisposition, obesity, and smoking as independent risk factors for psoriasis in patients with breast cancer.

Interpretation

Previous studies have reported a higher risk of skin disorders such as dermatitis and skin infection in patients with breast cancer [27, 28]. We found a slightly increased risk of psoriasis in breast cancer patients as compared to the general population. However, the overall incidence of psoriasis is low, and the absolute risk differences observed were also rather small. Of note, the cumulative incidence estimates of the current study are based on primary clinical diagnoses of psoriasis from the patient register (1%) and are lower than the estimate reported in a previous study (13%) using skin screening results [7]. The use of a clinical definition may have resulted in underestimation of the incidence estimates while capturing the more severe cases.

The increased risk of psoriasis after breast cancer is clinically plausible, as some treatments for breast cancer can cause dermatological side effects. In the regional cohort, we found an association between radiotherapy and risk of psoriasis. Skin trauma (a burn, scratch, bruise, cut, etc.) has been reported as a triggering factor for 43–76% of incident psoriasis cases [12]. The highest risk of psoriasis within the first year after diagnosis could also partly be explained by trauma caused by ionizing radiation. Compared to lumpectomy, we observed a significantly higher risk of psoriasis in breast cancer patients with mastectomy in the multivariable model. Patients with mastectomy usually experience more wound complications and delayed wound healing [29]. As the two main pathogenic features of psoriasis (abnormal keratinocyte differentiation and hyperproliferation of keratinocytes) are also secondary to the altered development of the normal wound healing process [30], prolonged wound healing could trigger psoriasis onset. Additionally, an increased risk of psoriasis could be explained by psychological reactions to the disease diagnosis and treatment decision, since a severe stressful life event has been identified as a potential trigger for psoriasis [31]. Both factors (treatment and stress reaction to the actual diagnosis) could potentially explain the observed peak in psoriasis incidence shortly after diagnosis.

Our study further identified obesity, smoking, and a high genetic predisposition as independent risk factors of psoriasis in patients with breast cancer. Psoriasis is a highly heritable disease; the heritability rate is estimated to be 70% [13]. Previous studies have reported substantially higher relative risks of psoriasis when comparing the highest to the lowest quartile of the PRS, with risks being inversely correlated to the age of psoriasis diagnosis [17, 32, 33]. Although these results are not directly comparable to our findings, lower relative risks with genetic predisposition are anticipated in our study population because of the older age at psoriasis onset (after diagnosis of breast cancer). Smoking and increased BMI are also established risk factors for psoriasis in the general population [34]. The effect of smoking and obesity in the breast cancer cohort was comparable to effects previously observed in the general population [14, 16].

The main strength of our study is the large sample size and the population-based design using Swedish health registers, which minimizes selection and information biases. Other strengths include the abundant information of treatment, lifestyle, and genetic information in the regional breast cancer cohort. We also acknowledge several limitations. The validity (positive predictive value) of psoriasis diagnoses in the Swedish Patient Register is about 81% [19], which indicates a possibility of misclassification (e.g., misclassified radio dermatitis as psoriasis). Although mild cases of radio dermatitis and psoriasis have some symptoms in common (erythema on the skin and sometimes desquamation), severe psoriasis is quite different from radio dermatitis [35], and in contrast to dermatitis, does not disappear after a couple of weeks. As the patient register mostly includes the severe cases of psoriasis, this misclassification should not have influenced our results. Furthermore, because of increased medical surveillance, breast cancer patients may have received a diagnosis that would, in a healthy person, continue to be undiagnosed. However, the long-term risk of psoriasis vulgaris (up to 12 years) argues against surveillance bias being a pure explanation for the increased psoriasis risk observed.

Conclusions

The overall risk of psoriasis is slightly increased among patients with breast cancer compared to the general population. While the relative risk of psoriasis is highest within the first year of diagnosis, the risk of psoriasis vulgaris remained increased up to 12 years. Independent risk factors of psoriasis in breast cancer patients are radiotherapy, mastectomy, smoking, obesity, and a high genetic predisposition. Our findings emphasize the complex etiology of psoriasis in patients with breast cancer.

Abbreviations

ICD: 

International Classification of Diseases

CI: 

Confidence interval

HR: 

Hazard ratio

PRS: 

Polygenic risk score

SNP: 

Single nucleotide polymorphism

BMI: 

Body mass index

GWAS: 

Genome-wide association study

MAF: 

Minor allele frequency

OR: 

Odds ratio.

Declarations

Acknowledgements

This work was supported by the Swedish Research Council (grant no. 2014-2271), the Swedish Cancer Society (grant no. CAN 2016/684), and FORTE (grant no. 2016-00081). We would like to also acknowledge the Swedish Initiative for research on Microdata in the Social and Medical Sciences (SIMSAM), grant no. 80748301. Haomin Yang is supported by a grant from the China Scholarship Council (grant no. 201406010275). Jingmei Li is a recipient of awards from the Åke Wiberg Foundation and the Ollie och Elof Ericssons Foundation for Scientific Research.

Availability of data and materials

The register-based datasets linked and analyzed in the current study are not publicly available due to Swedish law, but are available by applying through the Swedish National Board of Health and Welfare and Statistics Sweden. Detailed information on data application is provided in the following links: http://www.socialstyrelsen.se/register/bestalladatastatistik/bestallaindividuppgifterforforskningsandamal and http://www.scb.se/sv_/Vara-tjanster/bestalla-mikrodata/.

Authors’ contributions

HY had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. KC and HY conceived and designed the study. All authors acquired, analyzed, or interpreted the data. HY and JSB drafted the manuscript. All authors critically revised the manuscript for important intellectual content. HY, JSB, JFL, EUM, and FC performed the statistical analysis. KC and HY obtained the funding. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/254-31/4). A subset of breast cancer patients within LIBRO-1 consented to participate in the questionnaire-based study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet
(2)
Department of Pediatrics, Örebro University Hospital

References

  1. Lindberg M, Isacson D, Bingefors K. Self-reported skin diseases, quality of life and medication use: a nationwide pharmaco-epidemiological survey in Sweden. Acta Derm Venereol. 2014;94(2):188–91.View ArticlePubMedGoogle Scholar
  2. Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013;168(6):1303–10.View ArticlePubMedGoogle Scholar
  3. Hrehorow E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012;92(1):67–72.View ArticlePubMedGoogle Scholar
  4. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol. 2007;25(6):547–54.View ArticlePubMedGoogle Scholar
  5. Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res. 2016;25(11):2739–54.View ArticlePubMedGoogle Scholar
  6. Alolabi N, White CP, Cin AD. The Koebner phenomenon and breast reconstruction: Psoriasis eruption along the surgical incision. Can J Plast Surg. 2011;19(4):143–4.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Pastore F, Conson M, D'Avino V, Palma G, Liuzzi R, Solla R, Farella A, Salvatore M, Cella L, Pacelli R. Dose-surface analysis for prediction of severe acute radio-induced skin toxicity in breast cancer patients. Acta Oncol. 2016;55(4):466–73.View ArticlePubMedGoogle Scholar
  8. Schreiber GJ, Muller-Runkel R. Exacerbation of psoriasis after megavoltage irradiation. The Koebner phenomenon. Cancer. 1991;67(3):588–9.View ArticlePubMedGoogle Scholar
  9. Charalambous H, Bloomfield D. Psoriasis and radiotherapy: exacerbation of psoriasis following radiotherapy for carcinoma of the breast (the Koebner phenomenon). Clin Oncol. 2000;12(3):192–3.Google Scholar
  10. Tomlinson MJ. Psoriasis and radiotherapy. Clin Oncol. 2001;13(2):145.Google Scholar
  11. Cook C, Wongkittiroch K, Miller R. Erythrodermic psoriasis post radiation treatment: a case presentation and literature review. Practical Dermatology. 2011;10:36–8.Google Scholar
  12. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.View ArticlePubMedGoogle Scholar
  13. Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Heritability of psoriasis in a large twin sample. Br J Dermatol. 2013;169(2):412–6.View ArticlePubMedGoogle Scholar
  14. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304–14.View ArticlePubMedGoogle Scholar
  15. Brenaut E, Horreau C, Pouplard C, Barnetche T, Paul C, Richard MA, Joly P, Le Maitre M, Aractingi S, Aubin F, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:30–5.View ArticlePubMedGoogle Scholar
  16. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Yin X, Cheng H, Lin Y, Wineinger NE, Zhou F, Sheng Y, Yang C, Li P, Li F, Shen C, et al. A weighted polygenic risk score using 14 known susceptibility variants to estimate risk and age onset of psoriasis in Han Chinese. PLoS One. 2015;10(5):e0125369.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish National Inpatient Register. BMC Public Health. 2011;11:450.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Lofvendahl S, Theander E, Svensson A, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden—a population-based register study. PLoS One. 2014;9(5):e98024.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353–61. 361e351-352.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–8.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience. 2015;4(1):7.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373–80.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Holt J, Prentice R. Survival analyses in twin studies and matched pair experiments. Biometrika. 1974;61(1):17–30.View ArticleGoogle Scholar
  25. Sjolander A, Greenland S. Ignoring the matching variables in cohort studies — when is it valid and why? Stat Med. 2013;32(27):4696–708.View ArticlePubMedGoogle Scholar
  26. Cummings P, McKnight B. Analysis of matched cohort data. Stata J. 2004;4:274–81.Google Scholar
  27. Brand JS, Colzani E, Johansson AL, Giesecke J, Clements M, Bergh J, Hall P, Czene K. Infection-related hospitalizations in breast cancer patients: risk and impact on prognosis. J Infect. 2016;72(6):650–8.View ArticlePubMedGoogle Scholar
  28. Yoshikawa N, Inomata T, Shimbo T, Takahashi M, Uesugi Y, Juri H, Narumi Y. Appropriate evaluation of and risk factors for radiation dermatitis in breast cancer patients receiving hypofractionated whole-breast irradiation after breast-conserving surgery. Breast Cancer. 2014;21(2):170–6.View ArticlePubMedGoogle Scholar
  29. Vinton AL, Traverso LW, Jolly PC. Wound complications after modified radical mastectomy compared with tylectomy with axillary lymph node dissection. Am J Surg. 1991;161(5):584–8.View ArticlePubMedGoogle Scholar
  30. Ortonne JP. Aetiology and pathogenesis of psoriasis. Br J Dermatol. 1996;135 Suppl 49:1–5.View ArticlePubMedGoogle Scholar
  31. Naldi L, Peli L, Parazzini F, Carrel CF, Psoriasis Study Group of the Italian Group for Epidemiological Research in Dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol. 2001;44(3):433–8.View ArticlePubMedGoogle Scholar
  32. Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, Ellinghaus E, Barker JN, Chandran V, Dand N, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Chen H, Poon A, Yeung C, Helms C, Pons J, Bowcock AM, Kwok PY, Liao W. A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One. 2011;6(4):e19454.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Naldi L, Chatenoud L, Linder D, Fortina AB, Peserico A, Virgili AR, Bruni PL, Ingordo V, Lo Scocco G, Solaroli C, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–7.View ArticlePubMedGoogle Scholar
  35. Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: a review of our current understanding. Am J Clin Dermatol. 2016;17(3):277–92.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement